---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-002799"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:17:45.523386+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma Q2 fiscal 2026 net loss $10.6M; EXXUA launch generates $0.2M initial revenue

## Summary
- Net revenue $15.2M, down 6% YoY; net loss $10.6M vs net income $0.8M, includes $8.2M derivative warrant liability loss.
- Adjusted EBITDA -$0.8M vs +$1.3M, driven by EXXUA launch investments; cash $30.0M.
- ADHD portfolio revenue $13.2M (down from $13.8M); pediatric $1.7M (down from $2.4M) due to marketing deemphasis.
- EXXUA launched Dec 2025; initial stocking revenue $0.2M; 40+ person sales force deployed targeting $22B MDD market.
- Cash and cash equivalents $30.0M, largely unchanged from $31.0M at June 30, 2025.

## SEC filing metadata
- accession: 0001437749-26-002799
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774926002799/0001437749-26-002799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774926002799/aytu20251124_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-002799
- JSON: https://secwatch.observer/filing/0001437749-26-002799.json
- Plain text: https://secwatch.observer/filing/0001437749-26-002799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.